Lupin gets a boost from US pharma regulator

| Updated on January 23, 2018 Published on August 27, 2015


Shares of Lupin are likely to remain in focus on Friday, as the pharma major said it has received an approval from the US Food and Drug Administration to sell generic version of gastric ulcer drug Prilosec Delayed-Release capsules. In a stock market disclosure, Lupin said Prilosec had sales of $185 million (about ₹1,220 crore) in the US for the 12-month period ended June. The approval is Lupin’s third from the US in the last five days.

Published on August 27, 2015
This article is closed for comments.
Please Email the Editor